There are many things that raise red flags for angel investors. Here are a few examples.
The company was founded a long time ago
What have you been doing all this time?
If the company was founded 15 years ago and is still in the early stages, investors start wondering whether this is a forever science project rather than a venture-scale business. You had better have a compelling explanation for why the pace will accelerate now.
Time alone is not the problem. Lack of progress is.
The founders are related
Is it husband and wife? Father and son? Brother and sister?
The issue is not the family relationship itself. The concern is what happens when things go wrong. Can the company survive personal conflicts? And if both founders sit on the board, will they act independently or align against outside investors?
Good governance matters, especially during difficult moments.
Solo scientific founder
Why has nobody joined you yet?
A solo scientific founder raises questions about leadership, recruiting ability, and commercial awareness. Building a life science company requires much more than strong science. Regulatory strategy, clinical execution, financing, reimbursement, and business development all matter.
Investors want to know whether the founder recognizes those gaps and can build around them.
Founders fresh out of school
In the highly regulated life science industry, experience matters.
Having strong science is not the same as having a product. Having a molecule is not the same as having a drug.
Even after the hardest parts of product development are completed, reimbursement and commercialization can stall the company — and those are not typically taught in graduate school.
Young founders can still succeed, but self-awareness and surrounding themselves with experienced operators become critical.
High salaries for the management team
Do the founders have skin in the game?
Early-stage investors do not want to feel their capital is being used primarily to fund executive salaries. If management is already paying itself like a mature company, investors may question whether the founders are truly committed to the long haul.
Investors want to see founders succeed through equity, not by collecting big paychecks.
LLC structure
If you are raising venture financing, why is the company still an LLC?
It may be easier to start an LLC when you are testing ideas. However, staying as an LLC for too long signals inexperience, poor legal guidance, or a lack of preparation for institutional financing. Most venture-backed life science companies eventually become C-corps.
If you are serious about raising capital, convert to a C-corp before approaching investors.
Complicated financing structure
At the other extreme are companies with overly complicated licensing agreements or atypical financing terms. Investors want innovation in products, not in financing structures.
Messy cap tables, stacked SAFEs, unusual side agreements, excessive dilution, or overly engineered deal terms create friction for future financing rounds.
Keep the financing structure simple and the incentives aligned.
"We have no competition."
Really? Good markets attract competition.
Either you do not understand the competitive landscape, or you are working in a space that nobody cares about. Is there another product that addresses the unmet need from a different angle? Is there an emerging technology that will reduce the market or make your product obsolete?
Strong founders understand exactly where their products fit in the market and how they differentiate.
No data
Ideas are cheap. Unless you are an established industry veteran or a superstar from a well-known academic institute, raising money on concept alone is an uphill battle.
The reality is that many companies are seeking funding with promising drug candidates or innovative prototypes. There is no incentive for angels to take on undue risk based on your ideas alone.
If you are too early and have no traction with investors, start with government grants and friends & family.
Weak or outdated patent protection
Biotech investors care deeply about patent protection. Developing a healthcare product is costly and time-consuming. If the product succeeds, it needs to be able to defend against copycats.
Was the core patent filed ten years ago? How much exclusivity remains after the product has reached the market? Will there still be enough exclusivity left for a strategic acquirer to care? Work with a patent office to craft the patent filing strategy. Don't file it too early, and don't pitch to investors without any patent protection and a solid patent strategy.
Strong science without durable IP protection is not fundable.
Out-of-whack valuation and unrealistic timelines
Investors have seen hundreds of companies and dozens of pitch decks in your exact space. Outliers are easy to spot.
If your valuation is disconnected from comparable companies, your development timeline ignores regulatory realities, or your projected exit is based on unrealistic comps, credibility disappears quickly.
Do the homework. Get the valuation and timeline grounded in reality.
Angel investors invest early, but that does not mean they invest blindly. They invest their own hard-earned money into highly risky businesses. Their capital may be locked up for many years, with only a small chance of a successful exit. When facing hundreds of pitch decks, they develop pattern recognition to quickly filter out companies that raise alarm bells.
Angels are not looking for perfection. Any single red flag may be explainable. But each one lowers your odds of getting funded. In a market with unlimited ideas and limited capital, credibility matters. Don't show up with red flags to investors.